๐....stop..... Leave everything look at there Hereโs the latest analysis on Allogene Therapeutics, Inc. (NASDAQ: ALLO) โ a clinical-stage biotech stock focused on allogeneic CAR-T therapies. This summary blends current price, fundamentals, analyst views, technicals, and recent news (not investment advice).
---
๐ Current Market Snapshot
$ALLO price: ~$1.51 per share, slightly down intraday.
52-week range: roughly $0.86 โ $3.78 โ wide volatility typical for biotech developers.
Market cap & metrics: unprofitable biotech with negative EPS and no revenue base yet.
---
๐ Analyst Consensus & Price Targets
Wall Street outlook:
Consensus rating: Moderate Buy / Buy from most analysts.
12-month price targets: average ~$7.5 โ $8.8, with high estimates up to ~$14 โ implying a potential 400 %+ upside vs current price.
Some data shows buy ratings dominate, but there are hold/sell opinions too, reflecting uncertainty.
Analyst forecast highlights
Several analysts see $ALLO as significantly undervalued based on future prospects.
Long-term growth expectations are high only if pipeline successes materialize. $XRP #WriteToEarnUpgrade #BinanceAlphaAlert #BTCVSGOLD #BinanceBlockchainWeek #USJobsData
